ClinicalTrials.gov record
Active, not recruiting Phase 3 Interventional

Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)

ClinicalTrials.gov ID: NCT05925803

Public ClinicalTrials.gov record NCT05925803. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 22, 2026, 8:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Randomized, Parallel-group, Double-blind,Two-arm Phase III Study to Evaluate the Safety and Efficacy of Anifrolumab Compared With Placebo in Male and Female Participants 18 to 70 Years of Age Inclusive With Systemic Sclerosis

Study identification

NCT ID
NCT05925803
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
AstraZeneca
Industry
Enrollment
314 participants

Conditions and interventions

Interventions

  • Anifrolumab (blinded) Combination Product
  • Anifrolumab (unblinded, open label) Combination Product
  • Placebo (blinded) Drug

Combination Product · Drug

Eligibility (public fields only)

Age range
18 Years to 70 Years
Sex
All
Healthy volunteers
Not listed

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 7, 2023
Primary completion
Jan 5, 2027
Completion
Apr 4, 2028
Last update posted
Apr 19, 2026

2023 – 2028

United States locations

U.S. sites
26
U.S. states
16
U.S. cities
26
Facility City State ZIP Site status
Research Site Scottsdale Arizona 85259
Research Site Chula Vista California 91910
Research Site Los Angeles California 90095
Research Site Orange California 92868
Research Site Aurora Colorado 80045
Research Site New Haven Connecticut 06519
Research Site Washington D.C. District of Columbia 20007
Research Site Boca Raton Florida 33486
Research Site Fort Lauderdale Florida 33309
Research Site Gainesville Florida 32603
Research Site Jacksonville Florida 32216
Research Site Margate Florida 33063
Research Site South Miami Florida 33143
Research Site Tamarac Florida 33321
Research Site Chicago Illinois 60611
Research Site Kansas City Kansas 66160
Research Site New Orleans Louisiana 70121
Research Site Baltimore Maryland 21224
Research Site Ann Arbor Michigan 48109
Research Site Rochester Minnesota 55905
Research Site Babylon New York 11702
Research Site New York New York 10032
Research Site Cincinnati Ohio 45219
Research Site Pittsburgh Pennsylvania 15213
Research Site Allen Texas 75013
Research Site Houston Texas 77030

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 125 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05925803, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 19, 2026 · Synced Apr 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05925803 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →